摘要
目的:系统评价纳布啡用于术后镇痛的有效性和安全性,为临床合理用药提供循证参考。方法:计算机检索Embase、Medline、PubMed、中国学术期刊全文数据库、维普数据库和万方数据库,收集纳布啡(试验组)对比其他镇痛药(对照组)用于术后镇痛的随机对照试验(RCT)。经筛选文献、提取资料并按照改良的Jadad评分量表评价文献质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入10项RCT,共计796例患者。Meta分析结果显示,两组患者镇痛满意率[OR=1.11,95%CI(0.70,1.74),P=0.66]、恶心发生率[OR=1.20,95%CI(0.79,1.83),P=0.39]、呕吐发生率[OR=1.02,95%CI(0.69,1.50),P=0.92]、嗜睡发生率[OR=1.32,95%CI(0.47,3.76),P=0.06]比较,差异均无统计学意义;试验组患者皮肤瘙痒发生率[OR=0.29,95%CI(0.14,0.58),P=0.000 6]、呼吸抑制发生率[OR=0.21,95%CI(0.08,0.58),P=0.003]、尿潴留发生率[OR=0.05,95%CI(0.01,0.37),P=0.004]均显著低于对照组。结论:纳布啡用于术后镇痛的有效性和安全性均较好。
OBJECTIVE:To evaluate the efficacy and safety of nalbuphine for postoperative analgesia systematically,and to provide evidence-based reference in clinic.METHODS:Retrieved from Embase,Medline,PubMed,CNKI,VIP and Wanfang database,RCTs about nalbuphine hydrochloride(trial group)vs.other analgesics(control group)for postoperative analgesia were collected.After literature screening,data extraction and literature quality evaluation with modified Jadad scale,Meta-analysis was performed by using Rev Man 5.3 statistical software.RESULTS:A total of 10 RCTs were included,involving 796 patients.Results of Meta-analysis showed that there was no statistical significance in satisfaction rate of analgesia[OR=1.11,95%CI(0.70,1.74),P=0.66],the incidence of nausea[OR=1.20,95%CI(0.79,1.83),P=0.39],vomiting[OR=1.02,95%CI(0.69,1.50),P=0.92]or narcolepsy[OR=1.32,95%CI(0.47,3.76),P=0.06]between 2 groups.The incidence of pruritus[OR=0.29,95%CI(0.14,0.58),P=0.000 6],respiratory depression[OR=0.21,95%CI(0.08,0.58),P=0.003]and uroschesis[OR=0.05,95%CI(0.01,0.37),P=0.004]in trial group were significantly lower than control group.CONCLUSIONS:Nalbuphine has better efficacy and safety for postoperative analgesia.
作者
雷超
廖海燕
张朝辉
瞿星光
秦牧
LEI Chao;LIAO Haiyan;ZHANG Zhaohui;QU Xingguang;QIN Mu(The First College of Clinical Medical Sciences,China Three Gorges University/ICU of Yichang Central People’s Hospital,Hubei Yichang 443003,China;Medical College,China Three Gorges University,Hubei Yichang 443002,China)
出处
《中国药房》
CAS
北大核心
2019年第4期528-532,共5页
China Pharmacy
基金
国家自然科学基金资助项目(No.81400246)
宜昌市科技局项目(No.LA15301-06)
三峡大学学位论文培优基金资助项目(No.2018SSPY108)
